Aspire Biopharma Holdings (ASBP) Short term Debt (2023 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Short term Debt of $499214.0 for Q1 2026, little changed year-over-year from $499214.0 in Q1 2025, and down 61.32% quarter-over-quarter from $1.3 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Short term Debt (2023 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Short term Debt for 4 consecutive years, with $499214.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short term Debt changed 0.0% year-over-year to $499214.0; the TTM figure through Mar 2026 stood at $499214.0 (changed 0.0% YoY), while the FY2025 annual figure was $1.3 million, down 64.33% from the prior year.
- Short term Debt fell to $499214.0 in Q1 2026 per ASBP's latest filing, from $1.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $4.9 million in Q3 2024 and bottomed at $12384.0 in Q4 2023.
- Historically, Short term Debt has averaged $1.7 million across 4 years, with a median of $499214.0 in 2025.
- Annual changes were most pronounced in 2024 — Short term Debt soared 29111.14% — and 2025, when it plunged 64.33%.
- Aspire Biopharma Holdings' Short term Debt stood at $12384.0 in 2023, then jumped by 29111.14% to $3.6 million in 2024, then slumped by 64.33% to $1.3 million in 2025, then sank by 61.32% to $499214.0 in 2026.
- Business Quant data shows ASBP's Short term Debt at $499214.0 in Q1 2026, $1.3 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 499,214.00 |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 499,214.00 |
| Mar 31, 2025 | 499,214.00 |
| Dec 31, 2024 | 3.62 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Jun 30, 2024 | 427,788.00 |
| Mar 31, 2024 | 217,232.00 |
| Dec 31, 2023 | 12,384.00 |